- Home
- CII vs COLL Comparison
CII vs COLL Comparison
Compare CII & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CII
- COLL
- Stock Information
- Founded
- CII 2004
- COLL 2002
- Country
- CII United States
- COLL United States
- Employees
- CII N/A
- COLL 357
- Industry
- CII Investment Bankers/Brokers/Service
- COLL Biotechnology: Pharmaceutical Preparations
- Sector
- CII Finance
- COLL Health Care
- Exchange
- CII Nasdaq
- COLL Nasdaq
- Market Cap
- CII 804.5M
- COLL 947.6M
- IPO Year
- CII N/A
- COLL 2015
- Fundamental
- Price
- CII $20.39
- COLL $29.14
- Analyst Decision
- CII
- COLL Strong Buy
- Analyst Count
- CII 0
- COLL 5
- Target Price
- CII N/A
- COLL $43.80
- AVG Volume (30 Days)
- CII 78.8K
- COLL 304.8K
- Earning Date
- CII 01-01-0001
- COLL 05-08-2025
- Dividend Yield
- CII 6.17%
- COLL N/A
- EPS Growth
- CII N/A
- COLL N/A
- EPS
- CII N/A
- COLL 1.25
- Revenue
- CII N/A
- COLL $664,283,000.00
- Revenue This Year
- CII N/A
- COLL $20.00
- Revenue Next Year
- CII N/A
- COLL $3.74
- P/E Ratio
- CII N/A
- COLL $23.23
- Revenue Growth
- CII N/A
- COLL 17.17
- 52 Week Low
- CII $16.76
- COLL $23.23
- 52 Week High
- CII $19.81
- COLL $42.29
- Technical
- Relative Strength Index (RSI)
- CII 72.21
- COLL 53.67
- Support Level
- CII $19.44
- COLL $28.78
- Resistance Level
- CII $20.17
- COLL $29.57
- Average True Range (ATR)
- CII 0.20
- COLL 0.79
- MACD
- CII 0.02
- COLL -0.03
- Stochastic Oscillator
- CII 96.94
- COLL 36.56
About CII Blackrock Capital and Income Fund Inc.
Blackrock Enhanced Cap&Inc Fund, Inc is a closed-end management investment company. Its objective is to provide total return through a combination of current income and capital appreciation. The trust seeks to achieve its investment objective by investing a majority of its total assets in a portfolio of equity securities of U.S. and foreign issuers.
About COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.